Kura Oncology (KURA) Total Non-Current Liabilities (2022 - 2026)

Kura Oncology has reported Total Non-Current Liabilities over the past 5 years, most recently at $541.2 million for Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 43.48% to $541.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $541.2 million through Mar 2026, up 43.48% year-over-year, with the annual reading at $561.1 million for FY2025, 62.76% up from the prior year.
  • Total Non-Current Liabilities was $541.2 million for Q1 2026 at Kura Oncology, down from $561.1 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $561.1 million in Q4 2025 and troughed at $30.4 million in Q1 2023.
  • The 5-year median for Total Non-Current Liabilities is $52.3 million (2023), against an average of $210.5 million.
  • Year-over-year, Total Non-Current Liabilities grew 23.87% in 2024 and then surged 687.96% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $35.8 million in 2022, then skyrocketed by 42.49% to $51.0 million in 2023, then surged by 576.5% to $344.7 million in 2024, then surged by 62.76% to $561.1 million in 2025, then fell by 3.53% to $541.2 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Total Non-Current Liabilities are $541.2 million (Q1 2026), $561.1 million (Q4 2025), and $403.9 million (Q3 2025).